Anti-EPCAM CAR T-cell therapy - Sinobioway Cell Therapy

Drug Profile

Anti-EPCAM CAR T-cell therapy - Sinobioway Cell Therapy

Alternative Names: CAR T-cell therapy - Sinobioway Cell Therapy; CAR-T EPCAM therapy; Chimeric antigen T-cell therapies - Sinobioway Cell Therapy

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Sinobioway Cell Therapy
  • Class CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Gastric cancer

Most Recent Events

  • 13 Mar 2017 Sinobioway Cell Therapy suspends participant recruitment in a phase I/II trial in Gastric cancer (Late-stage disease) in China (NCT02725125)
  • 01 Nov 2015 Phase-I/II clinical trials in Gastric cancer (Late-stage disease) in China (IV) (NCT02725125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top